Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS proposes ASP+4% for hospital outpatient drugs

Executive Summary

CMS is proposing to lower the rate at which hospital outpatient drugs are reimbursed from the current average sales price plus 5 percent to ASP plus 4 percent for 2009. According to the outpatient prospective payment system proposed rule for 2009, released July 3, CMS is proposing "to continue our policy of making a combined payment for the acquisition and pharmacy overhead costs of separately payable drugs and biologicals at an equivalent average ASP-based amount calculated based on our standard methodology of estimating drug costs from claims." The agency added that ASP plus 4 percent "is the best currently available proxy for average hospital acquisition cost and associated pharmacy overhead cost.

You may also be interested in...



Increase In Pay For Part B Hospital Outpatient Drugs Needed, Groups Tell CMS

CMS' proposal to drop Medicare Part B drug reimbursement to average sales price plus 4 percent in the hospital outpatient setting is being met with calls for the agency to return to ASP plus 6 percent, the same rate physicians are reimbursed for drugs administered in their offices

Eleven Drugs Lose Medicare Part B Pass-Through Status In 2009 Proposal

CMS will issue its annual proposed changes to the list of drugs and biologicals designated as "pass-through" products under Medicare Part B, with 11 losing that status for 2009, 10 remaining on the list, and no drugs added

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel